HYTN Innovations Secures Major UK Cannabis Export Deal for 400kg GMP Products
January 14, 2025
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
HYTN Innovations has secured new import permits from the UK Home Office and export permits from Health Canada, enabling the export of over 400 kilograms of GMP cannabis products. This development marks HYTN’s strategic shift from a Canadian recreational cannabis producer to a global manufacturer of non-sterile pharmaceuticals.
The company’s focus on international distribution aligns with its April 2024 corporate update, emphasizing its commitment to meeting GMP standards and addressing global market demands. HYTN’s products meet both European and German Pharmacopoeia standards, demonstrating their quality commitment. The company expects to complete all permitted shipments by the end of Q1 2025.
HYTN Innovations ha ottenuto nuovi permessi di importazione dal Ministero dell’Interno del Regno Unito e permessi di esportazione da Health Canada, consentendo l’esportazione di oltre 400 chilogrammi di prodotti cannabis GMP. Questo sviluppo segna il cambiamento strategico di HYTN da produttore canadese di cannabis ricreativa a produttore globale di farmaci non sterili.
Il focus dell’azienda sulla distribuzione internazionale è in linea con l’aggiornamento aziendale di aprile 2024, che enfatizza il suo impegno a rispettare gli standard GMP e a rispondere alle esigenze del mercato globale. I prodotti di HYTN soddisfano sia gli standard della Farmacopea Europea che quella tedesca, dimostrando il loro impegno per la qualità. L’azienda prevede di completare tutte le spedizioni autorizzate entro la fine del primo trimestre del 2025.
HYTN Innovations ha asegurado nuevos permisos de importación del Ministerio del Interior del Reino Unido y permisos de exportación de Health Canada, lo que permite la exportación de más de 400 kilogramos de productos de cannabis GMP. Este desarrollo marca el cambio estratégico de HYTN de productor canadiense de cannabis recreativo a fabricante global de productos farmacéuticos no estériles.
El enfoque de la empresa en la distribución internacional se alinea con su actualización corporativa de abril de 2024, enfatizando su compromiso de cumplir con los estándares GMP y de atender la demanda del mercado global. Los productos de HYTN cumplen tanto con los estándares de la Farmacopea Europea como con los de la Farmacopea Alemana, lo que demuestra su compromiso con la calidad. La empresa espera completar todos los envíos permitidos antes del final del primer trimestre de 2025.
HYTN Innovations는 영국 내무부로부터 새로운 수입 허가와 Health Canada로부터 수출 허가를 획득하여 400킬로그램 이상의 GMP 대마초 제품 수출을 가능하게 했습니다. 이 발전은 HYTN이 캐나다의 레크리에이션 대마초 생산자에서 비내균성 의약품의 글로벌 제조업체로 전략적으로 전환하는 것을 의미합니다.
회사의 국제 유통에 대한 집중은 2024년 4월 기업 업데이트와 일치하며, GMP 기준 준수 및 글로벌 시장 수요에 부응하겠다는 의지를 강조합니다. HYTN의 제품은 유럽 및 독일 약전 기준을 모두 충족하여 품질에 대한 헌신을 보여줍니다. 회사는 2025년 1분기 말까지 모든 허가된 배송을 완료할 것으로 예상하고 있습니다.
HYTN Innovations a obtenu de nouveaux permis d’importation du ministère de l’Intérieur du Royaume-Uni et des permis d’exportation de Santé Canada, permettant l’exportation de plus de 400 kilogrammes de produits de cannabis GMP. Ce développement marque le tournant stratégique de HYTN, passant de producteur canadien de cannabis récréatif à fabricant mondial de médicaments non stériles.
Le focus de l’entreprise sur la distribution internationale s’aligne avec sa mise à jour corporative d’avril 2024, soulignant son engagement à respecter les normes GMP et à répondre aux demandes du marché mondial. Les produits de HYTN répondent aux normes de la Pharmacopée Européenne et Allemande, prouvant leur engagement envers la qualité. L’entreprise s’attend à compléter toutes les expéditions autorisées d’ici la fin du premier trimestre 2025.
HYTN Innovations hat neue Importgenehmigungen vom Innenministerium des Vereinigten Königreichs und Exportgenehmigungen von Health Canada erhalten, wodurch der Export von über 400 Kilogramm GMP-Cannabisprodukten ermöglicht wird. Dieser Schritt markiert den strategischen Wandel von HYTN vom kanadischen Produzenten von Freizeitchronen zu einem globalen Hersteller von nicht-sterilen Arzneimitteln.
Der Fokus des Unternehmens auf internationale Distribution steht im Einklang mit dem Unternehmensupdate von April 2024, das das Engagement betont, die GMP-Standards zu erfüllen und die Bedürfnisse des globalen Marktes zu adressieren. Die Produkte von HYTN entsprechen sowohl den europäischen als auch den deutschen Arzneibüchervorschriften, was ihr Engagement für Qualität beweist. Das Unternehmen erwartet, bis zum Ende des ersten Quartals 2025 alle genehmigten Sendungen abzuschließen.
Positive
- Secured new UK import and Canadian export permits for over 400kg of GMP cannabis products
- Strategic transformation from recreational to pharmaceutical-grade manufacturing
- Products meet European and German Pharmacopoeia standards
- Clear timeline for shipment completion by Q1 2025
Negative
01/14/2025 – 07:30 PM
VANCOUVER, British Columbia, Jan. 14, 2025 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a pharmaceutical company specializing in pharmaceutical-grade cannabis manufacturing is pleased to announce that it has received a new set of import permits from the United Kingdom’s Home Office and corresponding export permits from Health Canada. These permits enable the fulfillment of international orders totaling over 400 kilograms of Good Manufacturing Practice (GMP) cannabis products, advancing HYTN’s global reach and operational capabilities.
This development underscores HYTN’s strategic transformation from a cannabis producer primarily serving the Canadian recreational market to a global manufacturer of non-sterile pharmaceuticals. The Company’s focus on international distribution aligns with its corporate update published on April 5, 2024, which outlined its dedication to meeting stringent GMP standards and addressing the growing demands of regulated markets worldwide.
“HYTN consistently meets the standards of the European Pharmacopoeia and the German Pharmacopoeia (Deutsches Arzneibuch, DAB) reflecting our dedication to quality and global expansion,” states Jason Broome, Chief Operating Officer of HYTN. “With GMP systems and an efficient operational model, we are ready to meet the rising global demand for pharmaceutical-grade cannabis products.”
The Company expects to complete all shipments permitted by these permits by the end of Q1 2025, highlighting its ability to meet international demand on schedule.
About HYTN Innovations Inc.
HYTN Innovations Inc. is a pharmaceutical company that specializes in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybe-derived tryptamines. HYTN is dedicated to becoming a premier provider of these products across all federally regulated markets. The Company accomplishes this by strategically identifying market opportunities and effectively bringing innovative products to market through its advanced development platform.
About Good Manufacturing Practices (GMP)
GMP guidelines provide guidance for manufacturing, testing, and quality assurance to ensure that a manufactured product is safe for human consumption or use. Many countries have legislated that manufacturers follow GMP procedures and create their own GMP guidelines that correspond with their legislation.
For more information contact:
Elliot McKerr
Chief Executive Officer
1.866.590.9289
HYTN Investor Relations:
1.866.590.9289
investments@hytn.life
The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press release.
Certain information contained herein may constitute forward-looking statements that involve risks and uncertainties. Readers are cautioned not to place undue reliance on forward-looking statements, including, but not limited to, statements regarding the Company’s ability to fulfill or obtain purchase orders, and the Company’s expanded abilities to export its products globally. Factors that could cause actual results to vary from forward-looking statements or may affect the operations, performance, development, and results of the Company’s business include, among other things: the Company’s inability to fulfill or obtain purchase orders; the Company’s failure to generate sufficient cash flow from operations to meet its current and future obligations; the Company’s failure to access sources of debt and equity capital; changes to the regulatory framework within which the Company operates; competitive factors, pricing pressures, and supply and demand in the Company’s industry; and general economic and business conditions. Any statements that are not statements of historical fact are deemed to be forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and, except to the extent required by applicable law, the Company assumes no obligation to update or revise forward-looking statements made herein or otherwise, whether because of new information, future events, or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary note.
What is the volume of GMP cannabis products HYTN (HYTNF) is permitted to export to the UK?
HYTN has received permits to export over 400 kilograms of GMP cannabis products to the United Kingdom.
When will HYTN (HYTNF) complete its permitted UK cannabis shipments?
HYTN expects to complete all permitted shipments by the end of Q1 2025.
What pharmaceutical standards does HYTN (HYTNF) meet for its cannabis products?
HYTN meets both the European Pharmacopoeia and German Pharmacopoeia (Deutsches Arzneibuch, DAB) standards.
How has HYTN (HYTNF) transformed its business strategy in 2024?
HYTN has strategically transformed from a Canadian recreational cannabis producer to a global manufacturer of non-sterile pharmaceuticals.
HYTNF Rankings
HYTNF Latest News
HYTNF Stock Data
Search
RECENT PRESS RELEASES
Related Post
